RT Journal Article SR Electronic T1 Nationwide anti-tuberculosis drug resistance survey in the Republic of Azerbaijan JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P1432 VO 44 IS Suppl 58 A1 Irada Akhundova A1 Eljan Mammadbekov A1 Mehriban Seyfaddinova A1 Naila Aliyeva A1 Khanim Malikova YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P1432.abstract AB The overall goal of this anti-TB drug resistance survey is to provide representative data on the prevalence and risk factors of 1st and 2nd line anti-TB drug resistance patterns among TB patients in the Republic of Azerbaijan.WHO estimated of MDR-TB proportion among notified cases (22% and 56% MDR-TB among new and re treatment cases, respectively) based on the previous DRS results conducted between August 2006 and June 2007.A total of 544 sputum smear and/or culture positive TB patients need to be enrolled in the survey: 435 new and 109 newly registered re treatment patients from the civil sector. The enrollment plan is based on the number of new and re-treatment smear and/or culture positive cases reported in 2011 by the Republic of Azerbaijan.DRS survey covered the period from October 29 2012 to April 29 2013. Total number of diagnostic sputum samples, received by NRL is 1612. 810 of them are culture negatives/contamination, chronic cases, <15 years of age, NTM and duplicate cases. 802 of them are culture positive cases.Prevalence and 95% Confidence limits of resistance to first-line drugs among new (n=556), previously treated (N=246) and all TB cases (n=802) for MDR is accordingly 12,8%-CI(10,1-15,8); 28,5%-CI(22,9-34,5);17,6%-CI(15,0-20,4).Result: The results of current research shows that the percent of MDR-TB patients among new and retreated TB patients are accordingly 10.1-15.8 and 22.9-34.5. These indicators are sufficiently lower than the previous results provided by WHO.